Latest From Prasco Laboratories
Advisory committee will re-evaluate the continued marketing of AMAG Pharmaceuticals’ preterm birth drug after a failed confirmatory study; the last time an advisory committee weighed in on the future of an accelerated approval drug was for Avastin's breast cancer claim.
Two weeks after the product's approval, Mylan finally has launched Wixela and revealed a big price cut for the asthma and COPD medicine over the brand; the actual savings for patients remains dependent on payer negotiations and other factors.
Teva said the deal will close the first week of August, after agreeing to sell assets related to 79 pharmaceutical products to gain FTC clearance.
A federal judge tosses Takeda’s suit against FDA, finding Hikma did not need to reference Takeda’s Colcrys or certify Colcrys patents to obtain approval of its colchicine product.
- Generic Drugs
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Prasco Laboratories
- Senior Management
Christopher Arington, CEO
David Furniss, CFO
David R Vucurevich, Pres. & COO
- Contact Info
Phone: (513) 618-3333
6125 Commerce Ct.
Mason, OH 45040
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.